Dr. Mohanad Nada, or Dr. Mo as he likes to be called, is a medical specialist in immunopathology. He has completed extensive training and research in the field of cancer immunology and pathology in the US and other countries. He obtained his Ph.D. from Carver College of Medicine at the University of Iowa along with a Graduate Diploma in Public Health with special focus on cancer prevention. Before joining AUIS, Dr. Mo worked as a postdoctoral fellow in the Department of Internal Medicine at the University of Iowa. He has more than four years of active academic teaching experience in American and Iraqi universities. Dr. Mo was recently selected as an Obermann Graduate Institute for Advance Studies fellow. He is also an active member of several professional organizations, including the American Association of Cancer Research (AACR), American Association of Immunologists (AAI), and the Society of Immunotherapy for Cancer (SITC).
• Nada MH and Morita CT. PD-1 checkpoint blockade enhances the adoptive immunotherapy of human Vγ2Vδ2 T cells against human prostate cancer. (Manuscript being submitted)
• Nada MH, Wang H, Workalemahu G, Morita CT. Enhancing Adoptive Cancer Immunotherapy with Vγ2Vδ2 T Cells through Pulse Zoledronate Stimulation. Journal for ImmunoTherapy of Cancer 5.1 (2017): 9. https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0209-6
• Tanaka Y, Murata K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Science. 2017 Dec. https://onlinelibrary.wiley.com/doi/full/10.1111/cas.13491
• Workalemahu G, Wang H, Nada MH, Puan K-J, Kuzuyama T, Jones BD, Jin C, Morita CT. Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity. Journal of Immunology 2014; 193:708.
• Nada, MH. Prognostic value of IL-6 in breast cancer patients. TMJ 2010;17-23